Collegium Pharmaceutical
COLL
179 hedge funds and large institutions have $816M invested in Collegium Pharmaceutical in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 69 reducing their positions, and 12 closing their positions.
6,425% more call options, than puts
Call options by funds: $2.09M | Put options by funds: $32K
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
35% more capital invested
Capital invested by funds: $605M → $816M (+$211M)
7% more funds holding
Funds holding: 168 → 179 (+11)
3.15% less ownership
Funds ownership: 110.69% → 107.55% (-3.1%)
22% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$8.4M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$6.08M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$5.39M |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$4.99M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$47.4M |
| 2 |
Millennium Management
New York
|
-$8.65M |
| 3 |
CC
Clearline Capital
New York
|
-$2.45M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.86M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.85M |
COLL Hedge Fund Activity: Q4 2022 in Review
179 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2022, worth a combined $816M — up 35% from $605M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new COLL positions and 12 closed out — a net gain of 14 holders — while 54 added to existing stakes and 69 trimmed.
The largest buyer was Intrinsic Edge Capital Management, opening a new position worth an estimated $8.4M. The largest seller was Janus Henderson Group, cutting an estimated $47.4M.
- 179 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2022, up from 168 in Q3 2022.
- Funds reported $816M of Collegium Pharmaceutical stock for Q4 2022, up 35% quarter-over-quarter.
- 26 funds opened new Collegium Pharmaceutical positions in Q4 2022 and 12 closed out, a net change of +14 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2022 was Intrinsic Edge Capital Management, an estimated $8.4M added.
- The largest Collegium Pharmaceutical seller in Q4 2022 was Janus Henderson Group, an estimated $47.4M sold.
Based on aggregated 13F filings for Q4 2022.